加载中
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
常规交易时段
US$2.50
−US$0.15 · -5.66%
盘中时间采用ET。市场数据可能有所延迟。
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
日内区间
当前US$2.50
52周区间
当前US$2.50
盘中时间采用ET。市场数据可能有所延迟。
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
日内区间
当前US$2.50
52周区间
当前US$2.50
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4.2万 USD | 18.1万 USD | — | 13.4万 USD | 57.1万 USD |
| 销货成本 | 4.2万 USD | 17.2万 USD | 5.6万 USD | 16.5万 USD | 37.3万 USD |
| 毛利 | — | 9000 USD | −5.6万 USD | −3.1万 USD | 19.8万 USD |
| 研究与开发 | 600.4万 USD | 449.9万 USD | 445.4万 USD | 578.4万 USD | 677.1万 USD |
| 销售、一般及管理费用 | 552.5万 USD | 509.5万 USD | 443万 USD | 725.3万 USD | 569万 USD |
| 营业费用 | 1152.9万 USD | 959.4万 USD | 888.4万 USD | 1303.7万 USD | 1241.5万 USD |
| 利息收入 | — | 5.8万 USD | 3.1万 USD | 8.3万 USD | — |
| 利息支出 | — | — | — | — | 2.9万 USD |
| 折旧和摊销 | 3万 USD | 4.6万 USD | 5.6万 USD | 6.4万 USD | 5.3万 USD |
| 营业利润 | −1152.9万 USD | −958.5万 USD | −894万 USD | −1306.8万 USD | −1221.7万 USD |
| 净利润 | −1143.9万 USD | −954.1万 USD | −888.9万 USD | −1307.1万 USD | −1218.7万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$9.00
上涨空间 260.00%评级样本有限，仅4项
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
